HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology Advances with 8 Accepted Abstracts at EASL Congress 2024

HistoIndex Singapore

Company to deliver two oral and six poster presentations, including one TOP poster and one selected for poster tour, further reinforcing its leadership position in MASH digital pathology.HistoIndex's AI-driven solutions provide unprecedented insights into the direct prediction of patient clinical outcomes such as fibrosis progression, hepatic decompensation, and all-cause mortality.Company will host a breakfast meeting on June 5th to explore the transformative potential of stain-free digital pathology and AI in current MASH clinical trials and its prospective role in the clinical/treatment management of MASH patients post drug approval.View original content:https://www.prnewswire.co.uk/news-releases/histoindex-to-showcase-groundbreaking-ai-powered-stain-free-digital-pathology-advances-with-8-accepted-abstracts-at-easl-congress-2024-302159483.html